Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Cycloastragenol
81
CHF
CHF 81.00
In stock
CDX-C0592-M05050 mgCHF 81.00
CDX-C0592-M100100 mgCHF 129.00
| Product Details | |
|---|---|
| Synonyms | Astramembrangenin; Cyclogalegigenin; Cyclosieversigenin; Cyclosiversigenin; GRN510; TAT2 |
| Product Type | Chemical |
| Properties | |
| Formula |
C30H50O5 |
| MW | 490.73 |
| CAS | 84605-18-5 |
| Source/Host Chemicals | Plant |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in DMSO (10mg/ml), ethanol (3mg/ml) or DMF (10mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | WENNXORDXYGDTP-UOUCMYEWSA-N |
| Smiles | O[C@H]1C[C@@]2(C)[C@]3([H])C[C@H](O)[C@@]4([H])C(C)(C)[C@@H](O)CC[C@]45[C@]3(C5)CC[C@]2(C)[C@H]1[C@]6(C)O[C@H](C(C)(O)C)CC6 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Cycloastragenol is an aglycone of astragaloside IV isolated from Astragalus species. Extensive pharmacological effects have been attributed to cycloastragenol, including telomerase activation, telomere elongation, anti-inflammatory and anti-oxidative properties, improvement of lipid metabolism and wound repair promotion. It has been shown to inhibit endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation and NLRP3 inflammasome-mediated pyroptosis. It improved immune function in CD8+ T lymphocytes from HIV-1-infected patients. It might be a novel candidate for age-associated diseases.
Product References
(1) S.R. Fauce, et al.; J. Immunol. 181, 7400 (2008) | (2) J. Zhu, et al.; Drug Metab. Pharmacokinet. 25, 477 (2010) | (3) F.C. Ip, et al.; Neurosignals 22, 52 (2014) | (4) S. Wang, et al.; BBRC 450, 306 (2014) | (5) Y. Zhao, et al.; J. Ethnopharmacol. 169, 210 (2015) | (6) Y. Wan, et al.; Eur. J. Pharmacol. 833, 545 (2018) | (7) Y. Yu, et al.; Exp. Ther. Med. 16, 2175 (2018) | (8) G. Deng, et al.; Int. Immunopharmacol. 74, 105682 (2019) | (9) Y. Cao, et al.; Biomed. Res. Int. 2019, 7023950 (2019)